EPHICACYHEALTHOVYN™ Platform
Schedule a Call
Demo Viewer
Strategy
DV
Competitive Intelligence

A standing signal — not a one-time audit.

Weekly AI-harvested intelligence across paid media, organic search, AI answers, patient forums, and trade press. You give us a watchlist; we deliver continuous signal — archived to canon so the creative engine learns from it too.

Competitors tracked
12
Competitor A, Pfizer, Novartis, generics
+ 3 pipeline-adjacent biotechs
Signals · last 7 days
23
5 high-priority
Auto-classified by relevance
Forum mentions · Compound DT-204
187
illustrative trend
Reddit, patient groups, X/Twitter
Sentiment · last 30d
+0.62
once data flows
Range −1 to +1 · weighted by reach
Live feed

This week's intelligence

5 high8 med10 low
Competitor A · paid Meta● high · 2h ago
New disease-state campaign live targeting cardiology HCPs.
Creative emphasizes 'beyond steroids' positioning. 4 unique ad sets observed. Targeting US-only, 35–65, cardiology profession + 'rare cardiology indication' interest layer.
Direct competitorPaidHCP
Artifacts: 3 reels archived · 1 carousel · 6 frames archived
Generic rilonacept · search● high · 6h ago
Estimated launch volume tracking 14% above forecast.
New SEO push detected on 'rilonacept generic' (1,900 vol/mo). Amneal landing page now ranks #2 organic for the term. Compound DT-204 currently #9.
GenericSEOCost
Artifacts: Landing page snapshot · SERP archive · 04-26
ChatGPT · GEO scan● high · 9h ago
Compound DT-204 mentioned in 3 of 5 prompts on 'rare cardiology indication treatment.'
Competitor A mentioned 4 of 5. We're losing the AI surface. Specific erosion: 'best treatment for pericarditis flares' — Competitor A primary, Compound DT-204 tertiary. Recommend GEO-targeted content drop.
GEODirect competitorAI answers
Artifacts: Full prompt log · 50 prompts · Comparison table
Reddit · r/pericarditismed · 1d ago
23 mentions of 'cost' as primary barrier this week — up from 8 last week.
Caregiver subreddit driving the spike. Three distinct threads. Sentiment: frustrated but not anti-brand. Opportunity: caregiver-facing cost & access content.
Patient communityCostCaregiver
Artifacts: Thread links · 3 · Mention timeline
Pfizer pipeline · DT-387 adjacencymed · 1d ago
Phase 2 readout for IL-1 antagonist in pericarditis adjacent indication.
Worth flagging to medical. Not a direct rilonacept competitor today, but watching mechanism overlap given DT-387 trajectory.
PipelineMechanism overlap
Artifacts: Press release · Trial registry update
Watchlist

Who we're tracking

Competitor A (Kineret · anakinra)high
Direct competitor · 2h ago
New Meta campaign · 'beyond steroids' positioning
Generic rilonacept (Amneal · launch)high
Generic threat · 6h ago
Launch volume tracking 14% above forecast. New SEO push 'rilonacept generic'.
Pfizer (DT-387 adjacency)med
Pipeline adjacency · 1d ago
Phase 2 readout for IL-1 antagonist in adjacent indication.
Novartis (Ilaris)med
Adjacent IL-1 · 2d ago
EMA submission for new indication. US implications unclear.
Reddit · r/pericarditismed
Patient community · 1d ago
Cost discussion thread up 23 mentions/wk. Caregiver subreddit driving spike.
ChatGPT GEO surfacehigh
AI answers · 9h ago
Compound DT-204 mentioned in 3 of 5 prompts on RP treatment. Competitor A mentioned 4 of 5.
Cardiology Today (KOL site)low
Trade press · 3d ago
Editorial referenced steroid-overuse in RP. Compound DT-204 not cited.
Add or edit watchlist entries from theSettings panel.
Share of voice

Compound DT-204 vs the field, last 30 days

Compound DT-20442%
Competitor A (Kineret)36%
Generic rilonacept14%
Other / general medical8%
Share of digital mentions across paid, organic, social, AI answers, patient forums. Competitor A closing the gap on AI-answer surface specifically — addressed in Discovery → GEO.
Forward thisOne click to the right page for whoever you need to loop in.
Exec one-pager → CMOTrust & Compliance → SecurityEngagement → ProcurementTrack record → SkepticFAQ → AnyoneStart a pilot → Action
What's underneathArchitecture · advisors · published thinking.
Architecture Intelligence · Content Engine · Activation · MeasurementBrain Trust Named advisorsResearch Ephicacy Health · published
Talk to us30 minutes with Maha + Zein. No deck, no sales motion. We answer your questions.
Schedule a demo →hello@ephicacyhealth.com
OVYN · Content Studio for Pharma